A Phase 1, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of DWC202511 or DWC202512 on the Pharmacokinetics of DWP16001 and Its Metabolite in Healthy Adult Subjects
Latest Information Update: 15 Oct 2025
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 15 Oct 2025 New trial record